194 results on '"Silva Miguel, L"'
Search Results
2. EE78 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment Following Complete Resection and Platinum-Based Chemotherapy in Adult Patients With Early-Stage Non-Small Cell Lung Cancer With a High Risk of Recurrence
3. HPR52 Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action
4. EE443 Burden of Hospitalization Related to Adult Herpes Zoster Infection in Portugal
5. SA45 Natural Evolution of Chronic Kidney Disease in Diabetic Patients: Costs and Consequences in Portuguese Reality
6. EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal
7. HTA26 Portuguese Clinical Practice and Costs in the Treatment of Acid Sphingomyelinase Deficiency Disease
8. EE269 Evolution and Implications of the Portuguese HTA Framework on Health Economics in Patients’ Access to Innovation
9. HTA144 Evolution and Implications of the Portuguese HTA Framework on Added Therapeutic Value in Patients’ Access to Innovation
10. HSD65 Portuguese Clinical Practice in the Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
11. Convolutional Decoupled cVAE-GANs for Pseudo-Replay Based Continual Learning
12. Run-time Defragmentation for Dynamically Reconfigurable Hardware
13. Street pavement classification based on navigation through street view imagery
14. On-line Defragmentation for Run-Time Partially Reconfigurable FPGAs
15. Run-time generation of partial FPGA configurations for subword operations
16. Run-time generation of partial FPGA configurations
17. POSC397 Portuguese Clinical Practice in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer
18. POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal
19. POSA102 Burden of Disease and Cost of Illness of Spinal Muscular Atrophy in Portugal
20. POSC391 The Landscape of Non-Melanoma Skin Cancer in Portugal
21. POSB188 Burden of Disease and Cost of Illness of Alzheimer’S Disease in Portugal
22. POSA25 An Incremental Effectiveness Analysis of Avelumab in Combination With Axitinib for the Treatment of First-Line Advanced Renal Cell Carcinoma in Portugal
23. POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal
24. POSA178 The Impact of Non-Melanoma Skin Cancer in Portugal
25. POSB25 Public Health Benefit of Switching to High Dose Quadrivalent Vaccine for Influenza Seasonal Vaccination in Portuguese Elderly Population.
26. Caracterização do Cancro Cutâneo Não-Melanoma em Portugal
27. Support for partial run-time reconfiguration of platform FPGAs
28. PCN264 Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin in Combination with Daunorubicin and Cytarabine for the Treatment of Acute Myeloid Leukaemia in Portugal
29. PDG24 The Cost-Effectiveness of Isavuconazole in the Treatment of Invasive Fungal Infections in Portugal
30. PDG58 Incremental Effectiveness of Inotuzumab Ozogamicin for the Treatment of Relapsed or Refractory CD22-Positive B Cell Precursor Acute Lymphoblastic Leukaemia in Portugal
31. PCN60 Cost-Effectiveness of Avelumab in the Treatment of Patients with Metastatic Merkel Cell Carcinoma in Portugal
32. PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
33. PCN89 A Cost-Effectiveness Analysis of Atezolizumab in Combination with Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
34. PSS11 Costs and Quality of Life of RPE65-Mediated Inherited Retinal Dystrophies in Portugal
35. POSA397 Pharmacoepidemiological Study on the Use of Growth Hormone Therapy in Portuguese Paediatric Patients.
36. PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL
37. PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
38. PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL
39. PCN262 ESTIMATION OF THE NUMBER OF PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN PORTUGAL
40. PIN9 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
41. PNS17 ASSESSING TECHNOLOGIES THAT ARE EFFECTIVE BUT NOT COST-EFFECTIVE AT ZERO PRICE: AN ALTERNATIVE FRAMEWORK
42. PCN336 - TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
43. PND62 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
44. PIN45 - COST-EFFECTIVENESS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS
45. PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGAL
46. PIN119 - THERAPEUTIC SEQUENCES FOR THE TREATMENT OF PEOPLE LIVING WITH HIV TYPE 1 IN PORTUGAL
47. PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal
48. PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL
49. Acute Lymphoblastic Leukaemia’s Burden Of Disease In Portugal
50. Cost-Effectiveness of Pembrolizumab for The First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma in Portugal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.